High Dose "HDR-Like" Prostate SBRT: PSA 10-Year Results From a Mature, Multi-institutional Clinical Trial frontiersin.org/article/10.338…

Congratulations to Jennifer Ligibel for leading the ASCO Guidelines on Excercise, Diet and Weight Management during cancer treatment! Link: ascopubs.org/doi/abs/10.120…

Congratulations to my mentor Dr. Álvaro Martinez. For receiving gold medal Marie Curie. Proud of you. #ABSBrachy22 American Brachy

Radiotherapy 🏥is an often poorly understood #cancer treatment. But it is an essential, life saving treatment that >50% of all people will cancer 🦀 will benefit from. Here's how you can advocate for your loved ones in 4 easy steps: a thread🧵 #radonc 1/692

When a Urologist breaks ranks and recommends radiation... #treatmentsorkitchenappliances #blenderprocedureisnext #radonc

November 3, 10:00hr Lima #breastcancer #radonc #sbrt David Palma, MD, PhD Angel Montero Luis @Chubel13

“New” Kid on the Block: Interstitial Brachytherapy redjournal.org/article/S0360-…

𝗨𝗡 𝗖𝗔𝗠𝗣𝗘𝗢́𝗡 𝗔 𝗧𝗢𝗗𝗔𝗦 𝗟Ⓤ𝗖𝗘𝗦 🤩 Resumen de la histórica noche en la que conseguimos nuestra ⭐ 27. #ConLaUHastaElFinal #GrandeHayUnoSolo

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in

We are pleased to announce the recipients of 2025 Genitourinary Cancers Symposium Merit Awards to recognize first authors on top-ranking abstracts selected for presentation at the ASCO Genitourinary Cancers Symposium, 2/13–15, in San Francisco. Congrats! brnw.ch/21wQptf

Very happy and honored to receive this recognition for our active surveillance study. ASCO Conquer Cancer, the ASCO Foundation Very grateful to Dr. Andrew Loblaw and Danny Vesprini for allowing me to be part of this project. Sunnybrook Health Sciences Centre

Great day at #GU25. Presenting one of the oldest and largest active surveillance series for FIR prostate cancer. APP4 is a simple and accessible alternative for everyone. Dr. Andrew Loblaw Danny Vesprini

Active Surveillance for Favorable intermediate risk prostate cancer. Safe option for select patients. Data presented on #ESTRO25 Dr. Andrew Loblaw Danny Vesprini

Thank you so much for allowing me to be part of this great team. We continue to grow and show great evidence in the treatment of prostate cancer. Very proud to work with Dr. Andrew Loblaw

Congratulations Dr Gerard Morton on this well deserved recognition- 2025 Henschke Award recipient. We cannot be more proud of our Canadian Brachytherapy leaders @mirakeyes ⁦CBG⁩ ⁦Radiation Oncology⁩

We’re so proud of your vision and leadership Gerard!

Thrilled to complete my first year of fellowship! 🙌 Immense gratitude to all my mentors, especially Dr. Andrew Loblaw for shaping me into a better RadOnc. Honored to meet future RadOnc stars! 🌟

ANNOUNCING: The next #ISRSWebinar 📣 “Stereotactic Radiation in Gynecological Cancers: Metastasis, Adjuvant and Definitive Treatment” 🗓️ Tues, 23 September, 2025, 4pm CET 🥼Eric Leung, MD MSc FRCPC Eric Leung The goal of this presentation is to review the indications of

As expected people resist letting go of dogma. Lets review the common examples people grasp at: 1. Nodal field size: cited as why GETUG01 was negative (S1/S2), then cited why RTOG 9413 was negative (L5/S1), then POP-RT positive (L4/L5), but definitive trial of RTOG 0924 (L4/L5)

Rubén Del Castillo presenting active surveillance for men with low and intermediate risk #ProstateCancer Sunnybrook Health Sciences Centre N=1699, 18% GG2 mFU 9.4y 37% treated, 50 pts developed mets, 31 PC death APP4 1-5% had same low risk of M1 and PCM (compared to pure GG1) #ASTRO25